Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study
International Journal of Clinical Practice,  Clinical Article

Mattarozzi K et al. – This first prospective study provides objective data showing that early disclosure of multiple sclerosis diagnosis improves both the patient's quality of life and psychological well–being. In addition, the results seem to suggest that clinically isolated syndrome disclosure does not lead to the same favourable effects.

Methods
  • Eligible participants were all patients referred for the first time to the Neurological Unit who had manifested symptoms suggestive of MS for no more than 6 months.
  • All patients were evaluated for
    • QoL (SEIQoL and MS-QoL54).
    • Anxiety (STAI) and Depression (CMDI) on study inclusion (T0), 30 days after diagnosis disclosure (T30), and after 1 (T1y) and 2 (T2y) years' follow-up.

Results
  • Two hundred and twenty-nine patients were enrolled; 93 of these were unaware of their diagnosis.
  • Patients who already knew their diagnosis (100 with CIS and 22 with MS) were excluded from the main analyses and used to perform control analyses.
  • At the end of the screening, an MS diagnosis was disclosed to 18 of the 93 patients, whereas a CIS diagnosis was disclosed to 62 patients (12 patients received a diagnosis other than MS or CIS).
  • Thirty days after diagnosis disclosure, irrespective of the diagnosis disclosed, both QoL and Anxiety and Depression were significantly rated as better compared to the start of screening, (ps < 0.03), and this improvement remained stable over the two annual follow-ups.
  • However, as suggested by a significant `Time' × `Diagnosis' interaction with regard to both QoL and Anxiety and Depression (ps < 0.02), the effect of the disclosure in the short term differed depending on CIS or MS diagnosis.
  • Specifically, on MSQoL, which is a health-related QoL scale, the authors found a statically significant improvement, immediately after the diagnosis disclosure, in both the MS and CIS groups (ps < 0.01).
  • Differently, on SEIQoL, which is a non health-related QoL measure, and on the anxiety scale, the authors observed a statistically significant improvement only in the group which received a MS diagnosis (ps < 0.03).

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Psychiatry

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Psychiatry Articles

1 Levomilnacipran for the treatment of major depressive disorder: A review Full Text Neuropsychiatric Disease and Treatment, January 22, 2015    Free full text    Review Article

2 Cardiac effects of sertindole and quetiapine: Analysis of ECGs from a randomized double-blind study in patients with schizophrenia European Neuropsychopharmacology, January 21, 2015    Clinical Article

3 Faith-adapted psychological therapies for depression and anxiety: Systematic review and meta-analysis Journal of Affective Disorders, January 28, 2015    Evidence Based Medicine

4 Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: Outcome after long-term follow-up Psychiatry Research, December 3, 2014    Clinical Article

5 Are antidepressants equally effective in the long-term treatment of major depressive disorder? Human Psychopharmacology: Clinical and Experimental, December 8, 2014    Clinical Article

6 Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors Full Text Annals of General Psychiatry, January 29, 2015    Free full text    Clinical Article

7 Monoamine oxidase inhibitors for various psychiatric disorders and conditions Psychiatric Annals, January 9, 2015    Continuing Medical Education

8 Second-generation antipsychotic effect on cognition in patients with schizophrenia— A meta-analysis of randomized clinical trials Acta Psychiatrica Scandinavica, January 26, 2015    Evidence Based Medicine    Clinical Article

9 Impact of DSM-5 changes on the diagnosis and acute treatment of schizophrenia Schizophrenia Bulletin, January 7, 2015    Clinical Article

10 Cognitive differences in schizophrenia on long-term treatments with clozapine, risperidone and typical antipsychotics International Clinical Psychopharmacology, January 16, 2015    Clinical Article

11 Comparison of the effects of quetiapine extended-release and quetiapine immediate-release on cognitive performance, sedation and patient satisfaction in patients with schizophrenia: A randomised, double-blind, crossover study (eXtRa) Schizophrenia Research, January 20, 2015    Clinical Article

12 Cognitive training for attention-deficit/hyperactivity disorder: Meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials Journal of the American Academy of Child & Adolescent Psychiatry, January 8, 2015    Evidence Based Medicine

13 Is obsessive-compulsive symptomotology a risk factor for Alzheimer-type dementia? Psychiatry Research, January 2, 2015    Clinical Article

14 Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids Full Text Translational Psychiatry, January 19, 2015    Free full text    Clinical Article

15 Two novel CBTs for adolescents with ADHD: The value of planning skills European Child and Adolescent Psychiatry, January 14, 2015    Clinical Article

16 Is high prevalence of Vitamin D deficiency evidence for autism disorder?: In a highly endogamous population Full Text Journal of Pediatric Neurosciences, January 13, 2015    Free full text    Clinical Article

17 Is good insight associated with depression among patients with schizophrenia?: Systematic review and meta-analysis Schizophrenia Research, January 27, 2015    Evidence Based Medicine

18 Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: An integrated analysis of 15 clinical trials Journal of Psychopharmacology, December 2, 2014    Clinical Article

19 Biomarkers of intergenerational risk for depression: A review of mechanisms in longitudinal high-risk (LHR) studies Journal of Affective Disorders, January 30, 2015    Review Article

20 Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials JAMA Psychiatry, October 22, 2014    Evidence Based Medicine    Clinical Article

Indexed Journals in Psychiatry : Current Psychiatry, Bipolar Disorders, American Journal of Psychiatry, Addictionmore

Looking for a physician job? Let us help!

Register now for our free job placement service.
A career consultant will contact you soon.
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.
 

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List